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BACKGROUND
In January 2015, a total of 11 new diagnoses of human immunodeficiency virus 
(HIV) infection were reported in a small community in Indiana. We investigated 
the extent and cause of the outbreak and implemented control measures.
METHODS
We identified an outbreak-related case as laboratory-confirmed HIV infection 
newly diagnosed after October 1, 2014, in a person who either resided in Scott 
County, Indiana, or was named by another case patient as a syringe-sharing or 
sexual partner. HIV polymerase (pol) sequences from case patients were phyloge-
netically analyzed, and potential risk factors associated with HIV infection were 
ascertained.
RESULTS
From November 18, 2014, to November 1, 2015, HIV infection was diagnosed in 
181 case patients. Most of these patients (87.8%) reported having injected the ex-
tended-release formulation of the prescription opioid oxymorphone, and 92.3% 
were coinfected with hepatitis C virus. Among 159 case patients who had an HIV 
type 1 pol gene sequence, 157 (98.7%) had sequences that were highly related, as 
determined by phylogenetic analyses. Contact tracing investigations led to the 
identification of 536 persons who were named as contacts of case patients; 468 of 
these contacts (87.3%) were located, assessed for risk, tested for HIV, and, if in-
fected, linked to care. The number of times a contact was named as a syringe-
sharing partner by a case patient was significantly associated with the risk of HIV 
infection (adjusted risk ratio for each time named, 1.9; P<0.001). In response to 
this outbreak, a public health emergency was declared on March 26, 2015, and a 
syringe-service program in Indiana was established for the first time.
CONCLUSIONS
Injection-drug use of extended-release oxymorphone within a network of persons 
who inject drugs in Indiana led to the introduction and rapid transmission of HIV. 
(Funded by the state government of Indiana and others.)
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The epidemic of prescription opioid analgesic use and abuse in the United States over the past two decades1 has led 
to a marked increase in the incidence of death 
from opioid analgesic poisoning, with a quadru-
pling of the incidence from 1999 through 2011.2 
In 2009, for the first time, deaths from drug 
overdose (37,004 deaths, of which 60% were re-
lated to the use of opioids) outnumbered deaths 
from motor vehicle accidents in the United 
States.3,4 This epidemic of prescription opioid 
analgesic abuse has led to increases in the num-
bers of persons who inject drugs, as persons 
transition from oral use of opioids to insuffla-
tion (i.e., snorting or sniffing) to injection use.5-8 
Hepatitis C virus (HCV) is the most common 
infection transmitted through drug injection, 
and a large proportion of new HCV infections 
are associated with injection-drug use.9-13 In the 
United States, the number of cases of acute HCV 
infection reported from 2010 through 2013 in-
creased by 151%,10 and these increases have oc-
curred disproportionately among young persons, 
30 years of age or younger, who reside in non-
urban areas14 east of the Mississippi River, par-
ticularly within central Appalachia.15 These com-
munities have also historically had a very low 
prevalence of human immunodeficiency virus 
(HIV) infection.16
On January 23, 2015, the Indiana State De-
partment of Health (ISDH) began investigating a 
cluster of 11 newly diagnosed HIV infections, 
which was identified by an alert disease inter-
vention specialist, among residents of a small 
rural community in Scott County,17 where only 
5 HIV infections had been diagnosed from 2004 
through 2013 (Office of Clinical Data and Re-
search, Division of HIV/STD, ISDH: unpublished 
data). All 11 HIV-infected persons reported hav-
ing injected the extended-release formulation of 
the prescription opioid oxymorphone. An inves-
tigation that included contact tracing and phylo-
genetic analyses of HIV and HCV sequences was 
conducted to determine the extent and cause of 
this outbreak and to institute control measures.
Me thods
Oversight
The investigation of this outbreak was part of a 
response to a public health emergency. As such, 
the investigation was approved by the Centers 
for Disease Control and Prevention (CDC) in ac-
cordance with federal human subjects protection 
regulations and CDC policies and procedures18,19; 
review by an institutional review board was not 
required. Informed consent for research was not 
obtained because the activity was determined not 
to be research. Routine consents for HIV testing 
(oral or written, depending on the setting) and 
for contact tracing (oral) were obtained. All the 
authors vouch for the integrity and completeness 
of the data and analyses.
Case Definition, Contact Tracing,  
and Case Finding
We defined an outbreak-related case as laboratory-
confirmed HIV infection newly diagnosed after 
October 1, 2014, in a person who either resided 
in Scott County, Indiana (estimated population, 
14,799 persons 18 to 65 years of age in 2014), or 
was named by another case patient as a syringe-
sharing or sexual partner. A disease intervention 
specialist asked case patients to identify persons 
with whom they had shared syringes or had sex 
in the previous 12 months, as well as any social 
contacts who might benefit from HIV testing. 
Using this information, the disease intervention 
specialist located the contacts in the community 
and offered them point-of-care HIV testing. Dia-
grams of the connections between case patients 
and the contacts were made so that we could 
visualize the networks of syringe-sharing and 
sexual contacts (see the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org). We interviewed case patients and 
contacts to ascertain information with respect to 
drug use and sexual behavior. Deidentified data 
were maintained in a password-protected and 
physically secured electronic database.
Screening for HIV and HCV Infection
Before this outbreak, free HIV testing had not 
been available in this community since a Planned 
Parenthood clinic closed in 2013. Five HIV testing 
sites were established in response to this out-
break. Initial point-of-care screening was con-
ducted in most persons with the use of an oral 
fluid (OraQuick Advance Rapid HIV-1/2 Antibody 
Test, OraSure Technologies). Venous blood spec-
imens from persons who had nonreactive point-
of-care rapid tests were sent to a central labora-
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tory (ISDH Laboratories) to be tested for early 
and acute HIV infection with the use of a third-
generation HIV enzyme immunoassay (VITROS 
Anti-HIV 1+2 Assay, Ortho Clinical Diagnostics) 
and a pooled HIV type 1 (HIV-1) RNA assay (Ap-
tima HIV-1 RNA Qualitative Assay, Hologic) that 
included 256 specimens (estimated lower limit 
of quantification, 7680 HIV-1 copies per milli-
liter); if the pool tested positive, it was decon-
structed to identify the individual positive speci-
men.20 HIV infection was considered to be present 
if a point-of-care or laboratory HIV assay was 
reactive and was confirmed by either the Multi-
spot HIV-1/HIV-2 Rapid Test (Bio-Rad Laborato-
ries) or an individual HIV-1 RNA test. The recency 
of the HIV infection was determined by means of 
avidity testing (modified Bio-Rad HIV-1/HIV-2 
Plus O assay).21 All venous blood specimens were 
also tested for HCV antibody (with the use of the 
VITROS Anti-HCV assay [Ortho Clinical Diag-
nostics]), hepatitis B virus (HBV) surface antigen 
(VITROS HBsAg assay, Ortho Clinical Diagnos-
tics), and syphilis (Sure-Vue RPR, Fischer Health-
Care). Additional details on screening for HIV 
and HCV infection are provided in the Methods 
section in the Supplementary Appendix.
Molecular Laboratory Investigation
HIV-1 RNA was extracted from serum or plasma 
with the use of a QIAamp viral RNA mini kit 
(Qiagen), according to the manufacturer’s in-
structions. Partial polymerase (pol) sequences 
(approximately 915 bp) were amplified by means 
of polymerase chain reaction and sequenced as 
described previously.22 For HIV-1 pol reference 
sequences, we used sequences associated with 
infections that were diagnosed in Indiana coun-
ties other than Scott County by the ISDH Labo-
ratories, as well as sequences that we identified 
in a search of the GenBank database using Basic 
Local Alignment Search Tool (BLAST) software.23 
Sequences were aligned with the use of Molecu-
lar Evolutionary Genetics Analysis version 6.0 
(MEGA6) software,24 and we performed phylo-
genetic analysis using the program FastTree, 
version 2.1.25 Trees were visualized with the use 
of FigTree software, version 1.4.26 A phylogenetic 
cluster was defined when HIV-1 pol sequences 
shared nucleotide identity of greater than 97%, 
with a Shimodaira–Hasegawa probability of great-
er than 0.99. The presence of antiretroviral drug 
resistance mutations in the pol sequences was 
assessed with the use of the Stanford University 
HIV Drug Resistance database service Sierra, 
version 7.0.1.27
The HCV NS5B genomic region (300 bp) was 
amplified by polymerase chain reaction with in-
house specific primers and was sequenced with 
the use of a BigDye chemistry sequencing kit, 
version 3.1 (Applied Biosystems), with an auto-
mated sequencer (ABI 3130xl genetic analyzer, 
Applied Biosystems), as described previously.28 
Maximum likelihood phylogenetic trees were 
constructed with the use of MEGA6 software.24 
The NS5B sequences were used to classify HCV 
strains into genotypes and subtypes by phyloge-
netic analysis with HCV NS5B reference se-
quences, which were obtained from the Division 
of Viral Hepatitis of the CDC.
Statistical Analysis
We used the chi-square test, Fisher’s exact test, 
F-test, and the Kruskal–Wallis test to compare 
demographic variables and HIV risk factors be-
tween case patients and the contacts who were 
negative for HIV and had complete information. 
Variables that differed significantly according to 
HIV status were examined as potential risk fac-
tors; P values of less than 0.05 were considered 
to indicate statistical significance. Log-binomial 
regression modeling with stepwise backward 
elimination was used to estimate adjusted risk 
ratios. All analyses were conducted with the use 
of SAS software, version 9.3 (SAS Institute).
R esult s
Patients
From November 18, 2014, to November 1, 2015, 
we identified 181 outbreak-related HIV-1 infec-
tions. The first 3 cases were detected during 
routine HIV screening, and through the initial 
tracing of contacts, 8 more cases were diag-
nosed in syringe-sharing partners of these case 
patients. The number of new diagnoses peaked 
during March and April, which coincided with a 
surge in testing efforts, and then plateaued 
(Fig. 1). The median age of the case patients was 
34 years (interquartile range, 28 to 42), 57.5% 
were men, 98.9% were white, and 89.5% resided 
in Scott County (Table 1); the estimated preva-
lence of HIV among adults, 18 to 65 years of age, 
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in Scott County at that time was 1.1%. A total of 
159 of the 181 case patients (87.8%) reported 
injecting the prescription opioid oxymorphone 
in the previous 12 months (91.9% of the 173 case 
patients who reported injection-drug use). Per-
sons who reported injecting oxymorphone fre-
quently described crushing, dissolving, and cook-
ing extended-release oxymorphone (Opana ER, 
Endo Pharmaceuticals). Case patients also report-
ed injecting other drugs in the previous 12 months; 
among the 173 case patients who reported injec-
tion-drug use, 47 (27.2%) reported occasionally 
injecting heroin, 40 (23.1%) reported injecting 
methamphetamine, 15 (8.7%) reported injecting 
cocaine, and 2 (1.2%) reported injecting oxyco-
done. Among 77 female case patients, 19 (24.7%) 
reported exchanging sex for money or drugs in 
the previous 12 months. Overall, 167 case pa-
tients (92.3%) were coinfected with HCV, which 
included diagnoses that were made before and 
during the outbreak (Table 1).
Molecular Analysis
Molecular analysis of the HIV-1 pol gene in 159 
case patients who had available blood specimens 
revealed two clusters of HIV-1 subtype B infec-
Figure 1. Outbreak of HIV Infection in Southeastern Indiana.
Panel A shows the cumulative number of human immunodeficiency virus (HIV) infections associated with injection 
of the prescription opioid oxymorphone and the public health response, according to the date of diagnosis. DIS de-
notes disease intervention specialist. “Incident command established” indicates that the state health department 
used a standardized approach to the command, control, and coordination of the emergency response. Panel B shows 
the HIV diagnoses that were associated with injection of the prescription opioid oxymorphone among 180 patients, 
according to the week of testing. One patient was later determined to have received a diagnosis of HIV infection 
before the outbreak period and was excluded.
B HIV Diagnoses According to Week of Testing
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tion: cluster 1 comprised 157 sequences (98.7%) 
and cluster 2 comprised 2 sequences (Fig. 2). A 
subgroup of 48 sequences with 100% nucleotide 
identity was found within cluster 1. The 2 case 
patients who had sequences in cluster 2 reported 
no injection-drug use and were also not linked 
epidemiologically to the case patients who had 
sequences in cluster 1. Reference sequences ob-
tained from surrounding counties in Indiana and 
those that were identified in the GenBank data-
base search were not closely related to the se-
quences in the first cluster, a finding that is 
consistent with the outbreak being confined to 
Scott County. No major genotypic mutations 
that cause drug resistance were detected in any 
sequence. Among 125 case patients who had 
blood specimens available for recency testing, 
113 (90.4%) had infections that were classified 
as recent (defined as infection in the previous 
221 days). Among 113 case patients who had 
detectable HCV antibody levels and had blood 
specimens available for HCV molecular testing, 
76 (67.3%) had detectable HCV RNA levels con-
sistent with active HCV infection. Genotyping 
was performed on the sequences found in 67 of 
the 76 blood specimens, and the results showed 
that the most common genotype was genotype 
1a (50 sequences, which included a unique clus-
ter of 28 sequences and an additional 22 se-
quences that did not cluster), followed by geno-
type 3a (14 sequences, all of which formed a 
single cluster phylogenetically) and genotype 2b 
(3 sequences that did not cluster).
Contact Tracing Investigation
As of November 1, 2015, disease intervention 
specialists had identified 536 unique persons 
who were named as contacts by the 181 case pa-
tients; 468 (87.3%) of these contacts were located, 
assessed for risk, and tested for HIV infection 
(Fig. 3). A total of 287 contacts were found to 
be negative for HIV. In the 14 days preceding 
November 1, 2015, no new contact was named 
during the partner services investigations. The 
HIV-infected case patients and the contacts who 
were negative for HIV did not differ with respect 
to age (median age, 34 and 35 years of age, re-
spectively; P = 0.82) or sex (58% men and 56% 
men, respectively; P = 0.76). The HIV-infected 
case patients were more likely to be named as 
syringe-sharing partners than were the contacts 
who were HIV-negative (81% vs. 52%, P<0.001) 
and were less likely to be named as a sexual 
Variable Patients (N = 181)
Demographics
Age — no. (%)
<25 yr 26 (14.4)
25–34 yr 71 (39.2)
35–44 yr 55 (30.4)
≥45 yr 29 (16.0)
Median age (interquartile range) — yr   34 (28–42)
Sex — no. (%)
Male 104 (57.5)
Female 77 (42.5)
Race — no. (%)†
White 179 (98.9)
Other or missing data 2 (1.1)
County of residence — no. (%)
Scott County 162 (89.5)
Other county 19 (10.5)
Risk behaviors
Injection-drug use — no. (%) 173 (95.6)
Reported link to a partner with HIV infection — no. (%)
Sex only 1 (0.6)
Syringe sharing only 67 (37.0)
Sex and syringe sharing 97 (53.6)
No reported link 16 (8.8)
Female patients engaged in commercial sex work  
— no./total no. (%)
  19/77 (24.7)
Male patients having sex with men — no./total no. (%)   8/104 (7.7)
HIV clinical characteristics
Baseline HIV-1 viral load — no./total no. (%)
<10,000 copies/ml 11/153 (7.2)
10,000–100,000 copies/ml 46/153 (30.1)
100,001–1,000,000 copies/ml 91/153 (59.5)
>1,000,000 copies/ml 5/153 (3.3)
Median HIV-1 viral load — copies/ml 147,820
Interquartile range 48,763–369,763
Full range 70–10,000,000
Baseline CD4 cell count — no./total no. (%)
<200 cells/mm3 3/143 (2.1)
200–500 cells/mm3 39/143 (27.3)
>500 cells/mm3 101/143 (70.6)
Median CD4 cell count — cells/mm3 628
Interquartile range 446–809
Full range 17–1400
Other clinical characteristics — no./total no. tested (%)
Hepatitis C virus coinfection‡ 167/181 (92.3)
Reactive for hepatitis C virus RNA 76/113 (67.3)
Reactive for hepatitis B virus surface antigen§ 7/86 (8.1)
Reactive rapid plasma reagin test§ 2/77 (2.6)
*  HIV denotes human immunodeficiency virus.
†  Race was self-reported.
‡  Coinfection with hepatitis C virus was defined as a reactive test result for anti-
bodies to hepatitis C virus.
§  Case patients with detectable hepatitis B virus surface antigen were referred for 
care, and case patients with a reactive rapid plasma reagin test were treated.
Table 1. Demographic and Clinical Characteristics and Risk Behaviors of HIV-
Infected Persons — Southeastern Indiana, November 18, 2014, to November 1, 
2015.*
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partner only (1% vs. 15%, P<0.001). Among the 
287 contacts who were negative for HIV, 183 
(63.8%) were tested for HCV infection, of whom 
116 (63.4%) were found to be positive (see the 
Supplementary Appendix).
We analyzed a subgroup of 196 contacts who 
had been named by an HIV-infected case patient 
as a syringe-sharing partner and for whom in-
formation on risk behavior was collected at the 
time of HIV testing. The HIV-infected contacts 
and the contacts who were negative for HIV in-
fection were similar with respect to the rates of 
poverty (defined as an annual income <$10,000) 
(93% and 90%, respectively; P = 0.43) and incar-
ceration in the previous year (53% and 56%, re-
spectively; P = 0.64) (Table 2). In this subanalysis, 
HIV-infected contacts were also more frequent-
ly named as syringe-sharing partners by HIV-
infected case patients than were the contacts who 
were negative for HIV (median times named, 
4 vs. 1; P<0.001; adjusted risk ratio for each time 
named, 1.9; P<0.001).
Summary of Outbreak Response
In response to this outbreak, a public health 
emergency was declared on March 26, 2015, in a 
state of Indiana executive order (Fig. 1A).29,30 
Response efforts included the rapid expansion of 
free HIV and HCV testing and partner services, 
establishment of local HIV treatment services, 
provision of access to substance-use disorder 
treatment services, immediate access to health 
insurance, immunization services, executive gov-
ernmental actions (Executive Order 15-05), and 
general public education components (Table S1 
in the Supplementary Appendix). The number of 
HIV tests performed increased from 23 tests in 
November 2014 to 1838 tests between March 1 
and May 31, 2015 (>600 tests per month). The 
percentage of test results that were reactive de-
clined from 7.7% in March to 5.7% in April to 
0.8% in May. HIV screening among 582 inmates 
in eight county jails adjacent to Scott County 
identified two HIV infections (0.3%) that were 
phylogenetically and epidemiologically linked to 
the outbreak. In addition, pooled RNA testing 
identified three additional HIV-1 diagnoses (0.7%) 
in 429 specimens that tested negative for HIV 
antibody.
By March 31, 2015, the local medicine prac-
tice, with the support of specialists in infectious 
diseases, had initiated HIV care in this commu-
nity. Between April 4 and November 1, 2015, 
among 176 patients with HIV infection who 
could be monitored (i.e., they were alive and re-
siding in Indiana), 152 (86.4%) attended an HIV 
medical care appointment and 107 (60.8%) initi-
ated therapy with antiretroviral medications. By 
April 4, 2015, the local health department had 
established an emergency syringe-exchange pro-
gram (the first syringe exchange in the state of 
Indiana). During the period from April 4 to Oc-
tober 31, 2015, a total of 277 persons who in-
jected drugs enrolled in the program, and more 
than 97,000 sterile syringes were distributed and 
returned. The persons in the syringe-exchange 
program reported a median of 5 injections per 
day (interquartile range, 2 to 15).
Discussion
In this outbreak of HIV infections, the introduc-
tion of a single HIV-1 strain resulted in an explo-
sive transmission of HIV within a densely con-
nected network of persons who injected drugs 
and who shared syringes to inject the extended-
Figure 2 (facing page). Maximum-Likelihood Phylogenetic 
Tree of HIV-1 Polymerase Sequences — Southeastern 
Indiana, November 18, 2014, to November 1, 2015.
This figure diagrams the maximum-likelihood phyloge-
netic relationships of 159 HIV-1 polymerase (pol) se-
quences from case patients in southeastern Indiana 
who received a new diagnosis of HIV infection between 
November 18, 2014, and November 1, 2015, and who 
had a specimen available for sequencing (red-filled 
 circles); the diagram also includes local reference pol 
sequences from HIV infections diagnosed in Indiana 
counties other than Scott County (open red circles) 
and GenBank reference sequences identified with the 
use of Basic Local Alignment Search Tool (BLAST) 
software (black-filled circles). Branches of some refer-
ence sequences are collapsed (black-filled triangle) for 
better visualization of the complete tree, and the num-
ber of taxa in that branch are shown. Rooting of the tree 
was performed with the use of reference HIV-1 group M 
subtype C and J sequences. Confidence values for the 
branching pattern were assessed with the Shimodaira–
Hasegawa test and are given as probabilities to the left 
of each branching node. The unit for the scale bar of 
0.02 (solid line at bottom) is the number of nucleotide 
substitutions per nucleotide site. The phylogenetic 
analysis identified 157 sequences that formed a cluster 
(cluster 1; red-filled triangle opening to the box on the 
right), which was highly related (mean nucleotide iden-
tity, 99.7%). No Indiana or GenBank reference sequence 
was closely related to cluster 1.
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release formulation of the prescription oral opi-
oid oxymorphone. This outbreak prompted the 
state to declare a public health emergency that 
facilitated a rapid, multitiered public health re-
sponse that included immediate access to health 
insurance and HIV care and treatment, as well 
as the creation of a syringe-exchange program, 
in response to this HIV and HCV outbreak, that 
had previously been illegal under Indiana state 
law. Abuse and injection of prescription opioid 
analgesics was the root cause of this HIV outbreak, 
and these issues affect many communities.
The features of this outbreak offer several 
insights that may help prevent similar events in 
the future. First, the initial patients were detected 
during routine HIV screening and by an alert 
disease intervention specialist. This rapid detec-
tion highlights the importance of supporting 
and expanding critical public health services, 
especially HIV testing in rural communities in 
which the incidence of HIV is very low but injec-
tion-drug use related to the expanding opioid 
epidemic has disproportionately increased.31 Sec-
ond, the size of the network of persons who 
inject drugs and the extent of syringe sharing 
was unexpected, given the small population of 
the town. However, large networks of persons 
who inject drugs have been observed in other 
communities of similar size,9,11 which shows 
that such networks can be present in sparsely 
populated rural areas. Third, HCV infection was 
highly prevalent in this network of persons who 
inject drugs. Reports of new HCV infections 
should be noted because they can serve as mark-
ers of communities at risk for HIV, and interven-
tions to prevent further HCV infections, such as 
syringe-exchange programs, could possibly con-
tribute to reducing the risk of an HIV outbreak.32
A lack of health insurance could have been a 
barrier to the response to this outbreak, but for-
tuitously, in January 2015, Indiana received a 
waiver to provide Medicaid insurance under the 
Healthy Indiana Plan (HIP 2.0).33 HIP 2.0 helped 
to ensure health care coverage in the largely un-
insured and impoverished community that was 
affected by the outbreak and facilitated the im-
mediate enrollment, coverage, and access to criti-
cal health care services, including HIV treatment. 
Even with access to health insurance, a local 
HIV treatment provider, and care coordination, 
there were substantial challenges to the rapid 
initiation of therapy with antiretroviral medica-
tions.
The circumstances underlying this HIV out-
break are not unique to this community. Al-
though the magnitude of the outbreak was 
alarming, the introduction of HIV into a rural 
community in the United States was not unex-
pected when considered in the context of in-
creasing trends in injection use of prescription 
opioid analgesics1,4,7,9,11,14,34 and the new and steady 
rise in acute HCV infections in rural areas, par-
ticularly central Appalachia.15 In addition, al-
though approximately 50% of the persons who 
inject drugs in the United States are estimated to 
live outside major metropolitan areas, only an 
estimated 5.8% of syringes were exchanged in 
Figure 3. Syringe-Sharing Network of Persons with Newly Diagnosed HIV 
Infection.
This figure diagrams the network of 181 case patients in southeastern Indi-
ana who received a new diagnosis of HIV infection between November 18, 
2014, and November 1, 2015; the network is based on the syringe-sharing 
and sexual partners of the case patients at the time of their HIV diagnosis. 
The network comprises 536 unique persons and 1058 unique connections: 
841 of the contacts in this network (79.5%) were syringe-sharing contacts, 
81 (7.7%) were sexual contacts only, and 136 (12.8%) were syringe-sharing 
and sexual contacts. Reported contacts are represented by circles colored 
to reflect HIV status, and the sizes of the circles are proportional to the 
number of connections, with larger circles indicating more connections 
(range of number of connections, 1 to 56). Connections are represented by 
a solid gray line if the contact was a syringe-sharing contact only or a syringe-
sharing and sexual contact and by a dashed black line if the contact was a 
sexual contact only. The 83 “social contacts” in the bottom right are persons 
with no reported syringe-sharing or sexual connections to other members 
of the network. These social contacts were named by case patients as per-
sons the case patients knew who could benefit from an HIV test.
Social Contacts
Syringe sharing Sexual only
Connection Type
HIV+ HIV− Not tested
HIV Status
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rural locations.35 Resources related to the pre-
vention and treatment of HIV did not exist in 
this community before the outbreak, and, as in 
many rural communities, access to basic health 
care, substance-abuse treatment, and HIV pre-
vention services was limited.36
Proactive public health interventions are need-
ed to prevent or limit future HIV outbreaks in 
similar communities and should be designed on 
the basis of an integrated model that combines 
HIV and HCV testing and prevention education 
efforts with the use of antiretroviral medications 
for HIV treatment and preexposure prophylaxis, 
syringe-service programs, and treatment of sub-
stance-use disorder with medication-assisted treat-
ment37 (additional details are provided in the 
Supplementary Appendix). Substantial barriers to 
syringe exchange (i.e., laws prohibiting syringe 
exchange or syringe possession, lack of funding 
or of a community organization to implement 
the syringe exchange, and stigma) existed in this 
community before this outbreak. Although over-
coming these barriers may be challenging out-
side the context of an emergency response, recent 
changes in federal38 and state39 laws related to 
syringe exchange have created new opportunities 
to increase access. To prevent the expansion of HIV 
into rural networks of persons who inject drugs 
throughout the United States, it will be necessary 
to overcome these barriers to syringe exchange32 
and opioid-replacement therapy,40 strategies that 
are associated with a 56% and 64% reduction, 
respectively, in the risk of HIV infection.
The findings of this investigation may not 
necessarily be generalizable to networks of per-
sons who inject drugs who live in other com-
munities at risk. In this outbreak, the persons 
who injected drugs preferentially used extended-
release oxymorphone, the pharmacokinetic prop-
erties of which differ from those of other opiates 
and may be associated with more frequent injec-
tions and sharing of injection equipment among 
several persons (further details are provided in 
the Supplementary Appendix). In addition, the 
community of persons who injected drugs in 
this outbreak was relatively isolated from sur-
Variable
All 
(N = 196)
HIV-Positive 
(N = 100)
HIV-Negative 
(N = 96) P Value
Male sex — no. (%) 113 (57.7)   58 (58.0) 55 (57.3) 0.92
Median age (interquartile range) — yr 33 (27–41) 32 (27–40) 34 (26–42) 0.82
Non-Hispanic white — no. (%) 193 (98.5) 100 (100) 93 (96.9) 0.07
Annual income <$10,000 — no./total no. (%) 158/172 (91.9) 85/91 (93.4) 73/81 (90.1) 0.43
Incarcerated in past year — no./total no. (%) 104/192 (54.2) 52/99 (52.5) 52/93 (55.9) 0.64
Previously tested for HIV — no./total no. (%) 96/192 (50.0) 45/98 (45.9) 51/94 (54.3) 0.25
Reported injection-drug use — no. (%) 166 (84.7) 89 (89.0) 77 (80.2) 0.09
Shared drug-injection equipment — no. (%) 138 (70.4) 75 (75.0) 63 (65.6) 0.15
Sex without a condom — no. (%) 167 (85.2) 86 (86.0) 81 (84.4) 0.75
Sex with persons who exchange sex for money or 
drugs — no. (%)
18 (9.2) 11 (11.0) 7 (7.3) 0.37
Sex for money or drugs — no. (%) 17 (8.7) 9 (9.0) 8 (8.3) 0.87
Sex while on drugs — no. (%) 125 (63.8) 66 (66.0) 59 (61.5) 0.51
Sex with persons who inject drugs — no. (%) 125 (63.8) 68 (68.0) 57 (59.4) 0.21
Sex with HIV-infected persons — no. (%)  44 (22.4) 28 (28.0) 16 (16.7) 0.06
Sex with men who have sex with men — no. (%)  2 (1.0) 0 2 (2.1) 0.14
Median no. of times named as syringe-sharing 
partner (interquartile range)
2 (1–4) 4 (2–6) 1 (1–2) <0.001
*  Risk behavior during the previous 12 months was self-reported by the syringe-sharing partners with the use of a check 
box. The P values indicate whether the proportion of HIV-infected persons who selected that risk behavior differed from 
the proportion of HIV-negative persons who selected that risk behavior.
Table 2. Characteristics and Risk Behaviors of Persons Named as Syringe-Sharing Partners during Partner Services 
Investigations, According to HIV Status — Southeastern Indiana, November 18, 2014, to November 1, 2015.*
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rounding communities; only 10% of the persons 
who received a diagnosis of HIV infection resided 
outside Scott County, and all these persons had 
epidemiologic links to Scott County, most often 
through having used drugs in Scott County, ac-
cording to their reports. This geographic con-
finement limited the spread of this outbreak to 
surrounding counties but may not be representa-
tive of networks of persons who inject drugs in 
other rural areas.
In conclusion, this outbreak highlights the 
vulnerability of the growing numbers of persons 
who inject drugs in rural communities to the 
introduction and rapid transmission of HIV, as 
well as other bloodborne pathogens such as HCV 
and HBV. Although the proactive deployment of 
interventions for HIV prevention among persons 
who inject drugs is challenging in rural areas 
that have a low incidence of HIV but are at risk 
for an outbreak, the implementation of HIV test-
ing and treatment, syringe-service programs, and 
medication-assisted treatment are necessary to 
help prevent a similar outbreak in the future.
The findings and conclusions in this article are those of the 
authors and do not necessarily represent the views of the Cen-
ters for Disease Control and Prevention (CDC). The use of trade 
names and commercial sources is for identification only and 
does not imply endorsement by the CDC.
Supported (financially and in kind) by the state government 
of Indiana, the Scott and Clark County Health Departments, and 
the Department of Health and Human Services.
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